Status and phase
Conditions
Treatments
About
To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux disease in a multicenter, randomized, double-blind, comparative study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
The patients to be included will be outpatients who meet all of the following criteria. No specific gender is asked.
<For the observation period>
(3) Patients categorized in "grade M" (discoloring type: minimal change) according to the Los Angeles System (2nd Modification) for Classification of Reflux Esophagitis.
(4) Patients who are 20 years old or older at the time of obtaining consent. (5) Patients who are informed of the objective and details of the study and give written consent for study entry.
<For the treatment period>
Exclusion criteria
Patients who meet any of the following criteria will be excluded from the study.
Primary purpose
Allocation
Interventional model
Masking
288 participants in 3 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal